Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0046 | 0.4861 | 0.6469 |
Toxoplasma gondii | inositol(myo)-1(or 4)-monophosphatase 2, putative | 0.0037 | 0.3332 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.4024 | 0.4348 |
Loa Loa (eye worm) | hypothetical protein | 0.0039 | 0.3611 | 0.3902 |
Brugia malayi | Inositol-1 | 0.0037 | 0.3332 | 0.2367 |
Echinococcus multilocularis | inositol monophosphatase 1 | 0.0037 | 0.3332 | 0.4285 |
Trichomonas vaginalis | myo inositol monophosphatase, putative | 0.0037 | 0.3332 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0046 | 0.4861 | 0.6469 |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0037 | 0.3332 | 0.5 |
Trichomonas vaginalis | inositol monophosphatase, putative | 0.0037 | 0.3332 | 0.5 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0046 | 0.4861 | 0.6469 |
Schistosoma mansoni | hypothetical protein | 0.0021 | 0.0518 | 0.0242 |
Schistosoma mansoni | inositol monophosphatase | 0.0037 | 0.3332 | 0.3934 |
Schistosoma mansoni | bromodomain containing protein | 0.0064 | 0.7956 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0043 | 0.4357 | 0.4709 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.006 | 0.7332 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0046 | 0.4861 | 0.594 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0046 | 0.4861 | 0.594 |
Wolbachia endosymbiont of Brugia malayi | fructose-1,6-bisphosphatase | 0.0037 | 0.3332 | 0.5 |
Mycobacterium ulcerans | extragenic suppressor protein SuhB | 0.0037 | 0.3332 | 0.5 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0023 | 0.0851 | 0.0679 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0023 | 0.0851 | 0.0739 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0046 | 0.4861 | 0.4117 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0036 | 0.3186 | 0.4076 |
Brugia malayi | Bromodomain containing protein | 0.0039 | 0.3599 | 0.2673 |
Loa Loa (eye worm) | hypothetical protein | 0.0071 | 0.9254 | 1 |
Mycobacterium tuberculosis | Inositol-1-monophosphatase SuhB | 0.0033 | 0.266 | 0.5 |
Loa Loa (eye worm) | inositol-1 | 0.0037 | 0.3332 | 0.36 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0046 | 0.4861 | 0.5253 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.006 | 0.7332 | 1 |
Mycobacterium leprae | possible inositol monophosphatase SubH (IMPase) (inositol-1-phosphatase) (I-1-Pase ). | 0.0033 | 0.266 | 0.5 |
Entamoeba histolytica | myo-inositol monophosphatase, putative | 0.0037 | 0.3332 | 0.5 |
Loa Loa (eye worm) | PHD-finger family protein | 0.0021 | 0.0518 | 0.0559 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0046 | 0.4861 | 0.594 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0036 | 0.3186 | 0.4076 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0046 | 0.4861 | 0.6469 |
Trypanosoma cruzi | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0037 | 0.3332 | 0.5 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0023 | 0.0851 | 0.0739 |
Echinococcus granulosus | inositol monophosphatase 1 | 0.0037 | 0.3332 | 0.4285 |
Trichomonas vaginalis | myo inositol monophosphatase, putative | 0.0037 | 0.3332 | 0.5 |
Trypanosoma brucei | inositol-1(or 4)-monophosphatase 1, putative | 0.0037 | 0.3332 | 0.5 |
Leishmania major | myo-inositol-1(or 4)-monophosphatase 1, putative | 0.0037 | 0.3332 | 0.5 |
Schistosoma mansoni | inositol monophosphatase | 0.0037 | 0.3332 | 0.3934 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.